Medicamen Biotech PE ratio history and valuation
NSE: MEDICAMEQBSE: 531146Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹266.95.
30 Oct: open ₹269.75, high ₹274.00, low ₹255.00
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹360 Cr1,991st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.39%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 12,960
Medicamen Biotech's price to book, price to sales, EV to EBITDA and dividend yield on 30 Oct 2026, each against its own history of up to 10 years. Its P/E is not shown: the figures it needs for the twelve months to Jun 2026 are not complete or not comparable. The ratios use standalone accounts to Mar 2020 and consolidated from Mar 2021.
Medicamen Biotech PE ratio and valuation against its own history
- Price to earningsA results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
- Price to book1.31today
1 year
Median 1.36Today is at or above 41% of the 237 days
3 years
Median 2.65Today is at or above 16% of the 595 days
5 years
Median 3.62Today is at or above 9% of the 1,091 days
10 years, since Nov 2018
Median 4.31Today is at or above 5% of the 1,756 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.1.78today
1 year
Median 2.13Today is at or above 28% of the 247 days
3 years
Median 3.20Today is at or above 9% of the 731 days
5 years
Median 3.84Today is at or above 6% of the 1,227 days
10 years, since Jun 2017
Median 5.05Today is at or above 3% of the 2,070 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.19.39today
1 year
Median 25.78Today is at or above 30% of the 237 days
3 years
Median 29.32Today is at or above 12% of the 595 days
5 years
Median 34.15Today is at or above 7% of the 1,091 days
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.39%today
1 year
Median 0.36%Today is at or above 68% of the 247 days
3 years
Median 0.24%Today is at or above 89% of the 744 days
5 years
Median 0.19%Today is at or above 94% of the 1,240 days
10 years
Median 0.00%Today is at or above 97% of the 2,479 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹276 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹203 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹48 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹34 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹19 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.1,40,62,815at 27 Oct 2026
Consolidated accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Medicamen Biotech financials ›
Medicamen Biotech valuation at each year end
On the last trading day of each March, the month the company's year ends.Medicamen Biotech dividend history
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 546 | 678 | 567 | 221 | 652 | 783 | 834 | 486 | 610 | 303 |
| Price to earnings | No full year | 73.9 | 51.4 | No full year | 59.4 | 49.6 | 60.8 | Earlier quarters restated in the year | 82.8 | Earlier quarters restated in the year |
| Price to book | No balance sheet | No balance sheet | 7.0 | 1.9 | 5.1 | 5.6 | 4.5 | 2.4 | 2.8 | 1.1 |
| Price to sales | No full year | 6.5 | 4.8 | No full year | 5.7 | 6.9 | 6.7 | 2.8 | 3.4 | 1.8 |
| EV to EBITDA | No full year | No balance sheet | 33.8 | No full year | 37.4 | 35.1 | 37.2 | 21.8 | 29.4 | 23.8 |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.15% | 0.26% | 0.21% | 0.45% |
| Earnings yield | No full year | 1.4% | 1.9% | No full year | 1.7% | 2.0% | 1.6% | Earlier quarters restated in the year | 1.2% | Earlier quarters restated in the year |
Medicamen Biotech market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Book value and enterprise value
From the close on 30 Oct 2026.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹374 Cr
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹195.94
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- ₹1.00
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹207 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Medicamen Biotech is 112th among them by market cap. Each median leaves out Medicamen Biotech itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 27.6Across 158 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.1Across 144 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.49%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Infinium PharmachemINFINIUM | 438 | 36.04 | 3.62 | – | 0.00% |
 Albert DavidALBERTDAVD | 435 | 19.29 | 1.11 | 16.1 | 0.66% |
 Haleos LabsHALEOSLABS | 422 | 26.68 | 1.97 | 12.9 | 0.11% |
 Jenburkt PharmaceuticalsJENBURPH | 377 | 11.47 | 1.91 | 7.9 | 2.43% |
| Medicamen BiotechMEDICAMEQ | 360 | – | 1.31 | 19.4 | 0.39% |
 Astonea LabsASTONEALAB | 357 | 79.15 | 6.26 | – | 0.00% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 339 | – | – | – | 0.00% |
 Lyka LabsLYKALABS | 277 | – | 2.89 | 97.9 | 0.00% |
 Astal LaboratoriesASTALLTD | 270 | 27.77 | 0.81 | 18.7 | 0.00% |